Clinical Trial Update: Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

This entry notes a Phase 1/Phase 2 clinical trial combining fuzuloparib with arsenic trioxide for platinum-resistant relapsed ovarian cancer, which is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)
• Fuzuloparib

Snippet

Sponsor: Xing Xie | Conditions: Efficacy and Safety | Phase 1, Phase 2 | Status: RECRUITING